177 related articles for article (PubMed ID: 20693906)
1. Recent advances in pulmonary fibrosis: implications for scleroderma.
Homer RJ; Herzog EL
Curr Opin Rheumatol; 2010 Nov; 22(6):683-9. PubMed ID: 20693906
[TBL] [Abstract][Full Text] [Related]
2. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis.
Owens GR; Paradis IL; Gryzan S; Medsger TA; Follansbee WP; Klein HA; Dauber JH
J Lab Clin Med; 1986 Mar; 107(3):253-60. PubMed ID: 3950467
[TBL] [Abstract][Full Text] [Related]
3. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
Thachil J
Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
[TBL] [Abstract][Full Text] [Related]
4. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model.
Wuyts WA; Willems S; Vos R; Vanaudenaerde BM; De Vleeschauwer SI; Rinaldi M; Vanhooren HM; Geudens N; Verleden SE; Demedts MG; Thomeer M; Verbeken EK; Verleden GM
Exp Lung Res; 2010 Dec; 36(10):602-14. PubMed ID: 20874225
[TBL] [Abstract][Full Text] [Related]
5. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.
Chizzolini C
Ann Med; 2007; 39(1):42-53. PubMed ID: 17364450
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis.
Leslie KO
Arch Pathol Lab Med; 2012 Jun; 136(6):591-600. PubMed ID: 22136526
[TBL] [Abstract][Full Text] [Related]
7. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis.
Chizzolini C
Curr Opin Rheumatol; 2008 Nov; 20(6):707-12. PubMed ID: 18946333
[TBL] [Abstract][Full Text] [Related]
8. Current and future direction in the management of scleroderma.
Brady SM; Shapiro L; Mousa SA
Arch Dermatol Res; 2016 Sep; 308(7):461-71. PubMed ID: 27139430
[TBL] [Abstract][Full Text] [Related]
9. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.
Schachna L; Medsger TA; Dauber JH; Wigley FM; Braunstein NA; White B; Steen VD; Conte JV; Yang SC; McCurry KR; Borja MC; Plaskon DE; Orens JB; Gelber AC
Arthritis Rheum; 2006 Dec; 54(12):3954-61. PubMed ID: 17133609
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of idiopathic pulmonary fibrosis: from initial apoptosis of epithelial cells to lung remodeling?
Jin HL; Dong JC
Chin Med J (Engl); 2011 Dec; 124(24):4330-8. PubMed ID: 22340409
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?
Murray LA; Rubinowitz A; Herzog EL
Curr Opin Rheumatol; 2012 Nov; 24(6):656-62. PubMed ID: 22955020
[TBL] [Abstract][Full Text] [Related]
12. [Physiopathology of scleroderma].
Fleischmajer R; Perlish JS; Maquart FX; Kalis B
Ann Dermatol Venereol; 1993; 120(2):157-66. PubMed ID: 8363310
[TBL] [Abstract][Full Text] [Related]
13. Animal models of scleroderma: lessons from transgenic and knockout mice.
Derrett-Smith EC; Denton CP; Sonnylal S
Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
[TBL] [Abstract][Full Text] [Related]
14. [The mechanism of lung tissue remodeling in the progression of idiopathic pulmonary fibrosis].
Kogan EA; Tyong FV; Demura SA
Arkh Patol; 2010; 72(4):30-6. PubMed ID: 21086635
[TBL] [Abstract][Full Text] [Related]
15. 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis.
Gurrieri C; Piazza F; Gnoato M; Montini B; Biasutto L; Gattazzo C; Brunetta E; Cabrelle A; Cinetto F; Niero R; Facco M; Garbisa S; Calabrese F; Semenzato G; Agostini C
J Pharmacol Exp Ther; 2010 Mar; 332(3):785-94. PubMed ID: 19959748
[TBL] [Abstract][Full Text] [Related]
16. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma.
Wusirika R; Ferri C; Marin M; Knight DA; Waldman WJ; Ross P; Magro CM
Am J Clin Pathol; 2003 Oct; 120(4):596-606. PubMed ID: 14560571
[TBL] [Abstract][Full Text] [Related]
17. New developments in the pathogenesis of systemic sclerosis.
Sakkas LI
Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
[TBL] [Abstract][Full Text] [Related]
18. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
[TBL] [Abstract][Full Text] [Related]
19. Animal models of scleroderma: fresh insights.
Artlett CM
Curr Opin Rheumatol; 2010 Nov; 22(6):677-82. PubMed ID: 20720495
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
Sakkas LI; Chikanza IC; Platsoucas CD
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
